Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production

References

• Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. Accelerating next-generation vaccine development for global disease prevention. Science 2013; 340:1232910; PMID:23723240; http://dx.doi.org/10.1126/science.1232910
   PubMed Web of Science ®Google Scholar
• Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev Vaccines 2010; 9:157-73; PMID:20109027; http://dx.doi.org/10.1586/erv.09.160
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today 2015; 20:122-8; PMID:25450771; http://dx.doi.org/10.1016/j.drudis.2014.10.003
   PubMed Web of Science ®Google Scholar
• Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up. http://www.malariavaccine.org/pr2015Apr24-RTSS.php, 2015
   Google Scholar
• RTS SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31-45; PMID:25913272; http://dx.doi.org/10.1016/S0140-6736(15)60721-8
   PubMed Web of Science ®Google Scholar
• Tinto H, D'Alessandro U, Sorgho H. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31-45; http://dx.doi.org/10.1016/S0140-6736(15)60721-8
   PubMed Web of Science ®Google Scholar
• Whitacre DC, Espinosa DA, Peters CJ, Jones JE, Tucker AE, Peterson DL, Zavala FP, Milich DR. P. falciparum and P. vivax epitope-focused VLPs elicit sterile immunity to blood stage infections. PLoS One 2015; 10:e0124856; PMID:25933001; http://dx.doi.org/10.1371/journal.pone.0124856
   PubMedGoogle Scholar
• Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest 2010; 120:4168-78; PMID:21123952; http://dx.doi.org/10.1172/JCI44423
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malaria J 2009; 8:312; http://dx.doi.org/10.1186/1475-2875-8-312
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Eng J Med 2011; 365:1863-75; http://dx.doi.org/10.1056/NEJMoa1102287
   PubMed Web of Science ®Google Scholar
• Perdue ML, Arnold F, Li S, Donabedian A, Cioce V, Warf T, Huebner R. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines 2011; 10:1183-94; PMID:21854311; http://dx.doi.org/10.1586/erv.11.82
   PubMed Web of Science ®Google Scholar
• Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009; 37:182-9; PMID:19297194; http://dx.doi.org/10.1016/j.biologicals.2009.02.014
   PubMed Web of Science ®Google Scholar
• Gottlieb T, Ben-Yedidia T. Epitope-based approaches to a universal influenza vaccine. J Autoimmunity 2014; 54:15-20; http://dx.doi.org/10.1016/j.jaut.2014.07.005
   PubMed Web of Science ®Google Scholar
• Soema PC, van Riet E, Kersten G, Amorij JP. Development of cross-protective influenza a vaccines based on cellular responses. Frontiers Immunol 2015; 6:237; http://dx.doi.org/10.3389/fimmu.2015.00237
   PubMed Web of Science ®Google Scholar
• Morrison N. BioPharm Insight: BiondVax mulls partnership, funding and CMO options for universal flu vaccine Phase III – CEO. 2015. Available at http://www.biondvax.com/2015/07/02/biopharm-insight-biondvax-mulls-partnership-funding-and-cmo-options-for-universal-flu-vaccine-phase-iii-ceo/
   Google Scholar
• Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001–a novel universal influenza vaccine. J Clin Immunol 2012; 32:595-603; PMID:22318394; http://dx.doi.org/10.1007/s10875-011-9632-5
   PubMed Web of Science ®Google Scholar
• Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011; 42:1-8; PMID:21082230; http://dx.doi.org/10.1007/s11262-010-0547-7
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145-52; PMID:21624416; http://dx.doi.org/10.1016/j.vaccine.2011.05.041
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. Mbio 2010; 1:e00018-10; PMID:20689752
   PubMed Web of Science ®Google Scholar
• Sirskyj D, Diaz-Mitoma F, Golshani A, Kumar A, Azizi A. Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol Cell Biol 2011; 89:81-9; PMID:20458336; http://dx.doi.org/10.1038/icb.2010.65
   PubMed Web of Science ®Google Scholar
• Oyarzun P, Ellis JJ, Gonzalez-Galarza FF, Jones AR, Middleton D, Boden M, Kobe B. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases. Vaccine 2015; 33:1267-73; PMID:25629524; http://dx.doi.org/10.1016/j.vaccine.2015.01.040
   PubMed Web of Science ®Google Scholar
• Ndung'u T, Weiss RA. On HIV diversity. AIDS 2012; 26:1255-60; PMID:22706010; http://dx.doi.org/10.1097/QAD.0b013e32835461b5
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Mascola JR. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 2009; 4:347-51; PMID:20048696; http://dx.doi.org/10.1097/COH.0b013e32832f4a4d
   PubMed Web of Science ®Google Scholar
• Sanou MP, De Groot AS, Murphey-Corb M, Levy JA, Yamamoto JK. HIV-1 vaccine trials: evolving concepts and designs. Open AIDS J 2012; 6:274-88; PMID:23289052; http://dx.doi.org/10.2174/1874613601206010274
   PubMedGoogle Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med 2009; 361:2209-20; http://dx.doi.org/10.1056/NEJMoa0908492
   PubMed Web of Science ®Google Scholar
• Streeck H, D'Souza MP, Littman DR, Crotty S. Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med 2013; 19:143-9; http://dx.doi.org/10.1038/nm.3054
   PubMed Web of Science ®Google Scholar
• Rosa DS, Ribeiro SP, Cunha-Neto E. CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp 2010; 58:121-30; http://dx.doi.org/10.1007/s00005-010-0067-0
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; PMID:19012954; http://dx.doi.org/10.1016/S0140-6736(08)61591-3
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77; http://dx.doi.org/10.1086/428405
   PubMed Web of Science ®Google Scholar
• Altfeld M, Rosenberg ES. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 2000; 12:375-80; PMID:10899028; http://dx.doi.org/10.1016/S0952-7915(00)00103-5
   PubMed Web of Science ®Google Scholar
• Mann JK, Ndung'u T. HIV-1 vaccine immunogen design strategies. Virol J 2015; 12:3; PMID:25616599; http://dx.doi.org/10.1186/s12985-014-0221-0
   PubMed Web of Science ®Google Scholar
• Jin X, Newman MJ, De-Rosa S, Cooper C, Thomas E, Keefer M, Fuchs J, Blattner W, Livingston BD, McKinney DM, et al. A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults. Vaccine 2009; 27:7080-6; PMID:19786145; http://dx.doi.org/10.1016/j.vaccine.2009.09.060
   PubMed Web of Science ®Google Scholar
• Walker LE, Vang L, Shen X, Livingston BD, Post P, Sette A, Godin CS, Newman MJ. Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes. Vaccine 2009; 27:7087-95; PMID:19786132; http://dx.doi.org/10.1016/j.vaccine.2009.09.059
   PubMed Web of Science ®Google Scholar
• Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 2003; 171:5611-23; PMID:14607970; http://dx.doi.org/10.4049/jimmunol.171.10.5611
   PubMed Web of Science ®Google Scholar
• Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100-6; http://dx.doi.org/10.1038/nm1461
   PubMed Web of Science ®Google Scholar
• Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, Carlson KR, Mach L, Kong WP, McKee K, Yang ZY, et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 2012; 428:121-7; PMID:22521913; http://dx.doi.org/10.1016/j.virol.2012.03.012
   PubMed Web of Science ®Google Scholar
• Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, Goulder PJ, Ndung'u T, Barouch DH, Walker BD. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol 2011; 186:6914-24; PMID:21576505; http://dx.doi.org/10.4049/jimmunol.1004231
   PubMed Web of Science ®Google Scholar
• Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, Theiler J, Szinger J, Balachandran H, Buzby A, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-8; http://dx.doi.org/10.1038/nm.2108
   PubMed Web of Science ®Google Scholar
• Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Medicine 2010; 16:319-23; http://dx.doi.org/10.1038/nm.2089
   PubMed Web of Science ®Google Scholar
• Oyarzun P, Kobe B. Computer-aided design of T-cell epitope-based vaccines: addressing population coverage. Int J Immunogenet 2015; 42(5):313-21
   PubMed Web of Science ®Google Scholar
• Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 1998; 10:478-82; PMID:9722926; http://dx.doi.org/10.1016/S0952-7915(98)80124-6
   PubMed Web of Science ®Google Scholar
• Reche PA, Reinherz EL. PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res 2005; 33:W138-42; PMID:15980443; http://dx.doi.org/10.1093/nar/gki357
   PubMedGoogle Scholar
• Zhang GL, DeLuca DS, Keskin DB, Chitkushev L, Zlateva T, Lund O, Reinherz EL, Brusic V. MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles. J Immunol Methods 2011; 374:53-61; PMID:21130094; http://dx.doi.org/10.1016/j.jim.2010.11.009
   PubMed Web of Science ®Google Scholar
• Toussaint NC, Kohlbacher O. OptiTope–a web server for the selection of an optimal set of peptides for epitope-based vaccines. Nucleic Acids Res 2009; 37:W617-22; PMID:19420066; http://dx.doi.org/10.1093/nar/gkp293
   PubMedGoogle Scholar
• Molero-Abraham M, Lafuente EM, Flower DR, Reche PA. Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses. Clin Dev Immunol 2013; 2013:601943; PMID:24348677; http://dx.doi.org/10.1155/2013/601943
   PubMed Web of Science ®Google Scholar
• Vider-Shalit T, Raffaeli S, Louzoun Y. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Mol Immunol 2007; 44:1253-61; PMID:16930710; http://dx.doi.org/10.1016/j.molimm.2006.06.003
   PubMed Web of Science ®Google Scholar
• Buggert M, Norstrom MM, Czarnecki C, Tupin E, Luo M, Gyllensten K, Sönnerborg A, Lundegaard C, Lund O, Nielsen M, et al. Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage. PLoS One 2012; 7:e39874; PMID:22792193; http://dx.doi.org/10.1371/journal.pone.0039874
   PubMed Web of Science ®Google Scholar
• Toussaint NC, Maman Y, Kohlbacher O, Louzoun Y. Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation. Vaccine 2011; 29:8745-53; PMID:21875632; http://dx.doi.org/10.1016/j.vaccine.2011.07.132
   PubMed Web of Science ®Google Scholar
• Antonets DV, Bazhan SI. PolyCTLDesigner: a computational tool for constructing polyepitope T-cell antigens. BMC Res Notes 2013; 6:407; PMID:24107711; http://dx.doi.org/10.1186/1756-0500-6-407
   PubMedGoogle Scholar